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Short-chain fatty acids (SCFAs) are bacterial fermentation products, which are chemically composed by a carboxylic acid moiety
and a small hydrocarbon chain. Among them, acetic, propionic and butyric acids are the most studied, presenting, respectively,
two, three and four carbons in their chemical structure. These metabolites are found in high concentrations in the intestinal
tract, from where they are uptaken by intestinal epithelial cells (IECs). The SCFAs are partially used as a source of ATP by these
cells. In addition, these molecules act as a link between the microbiota and the immune system by modulating different aspects
of IECs and leukocytes development, survival and function through activation of G protein coupled receptors (FFAR2, FFAR3,
GPR109a and Olfr78) and by modulation of the activity of enzymes and transcription factors including the histone
acetyltransferase and deacetylase and the hypoxia-inducible factor. Considering that, it is not a surprise, the fact that these
molecules and/or their targets are suggested to have an important role in the maintenance of intestinal homeostasis and that
changes in components of this system are associated with pathological conditions including inflammatory bowel disease, obesity
and others. The aim of this review is to present a clear and updated description of the effects of the SCFAs derived from
bacteria on host immune system, as well as the molecular mechanisms involved on them.
Clinical & Translational Immunology (2016) 5, e73; doi:10.1038/cti.2016.17; published online 22 April 2016
Colonization of the skin, oral cavity, gastrointestinal, genital and
respiratory tracts by bacteria, viruses and fungi, microorganims
collectively referred as microbiota, is important for the proper
functioning of several physiological processes including host tissues
development, nutrient absorption and metabolism.1,2 Microbiota–host
interaction is also essential for the proper function of the immune
system. The development of immune cells, production of effector
soluble molecules such as antibodies, antimicrobial peptides and the
function of several components of host defense are modulated by the
microbiota.3 Taking this into account, it is not surprising that the loss
of this balance between host immune system and microbiota
components is associated with the development of infections and
inflammatory diseases such as periodontal disease, bacterial vaginosis,
inflammatory bowel disease, rheumatoid arthritis and obesity.4–6
Despite the advances in this field, the molecular mechanisms that
account for the interaction microbiota-immune system are not
completely understood. Microbial-associated molecular patterns
including lipopolysaccharide and peptidoglycans, metabolic molecules
including lactic acid and short-chain fatty acids (SCFAs), ATP and
others were described to play a role in this context.3,7,8 However, it has
been arduous to establish a relation between microbiota-derived
molecules, their host molecular targets and effects on normal and
pathological conditions since, among other factors, it is difficult to
distinguish their individual contribution to this multicomponent and
complex system.
One class of molecules that acts as a link between the microbiota
and the immune system is the SCFAs. These are bacterial fermentation
products, which are chemically composed by a carboxylic acid moiety
and a small hydrocarbon chain. The most common and most studied
of them are acetic, propionic and butyric acids, which have,
respectively, two, three and four carbons in their chemical structure.
The SCFAs are found in high concentrations in the intestinal tract,
where there is a dense population of bacteria that metabolizes
indigestible saccharides and, to a lesser extend other molecules, and
release the SCFAs as end products of the fermentation process.
Concentrations ranging from 70 to 140 mM in proximal colon and
20 to 70 mM in the distal colon have been described for the SCFAs
with a predominance of acetate in comparison to the other SCFAs.9 In
addition, SCFAs are also present in the oral cavity (from 6 to 38 mM of
acetate, 1 to 13 mM of propionate and 0 to 5 mM of butyrate) and
female genital tract (acetate concentrations may reach 120 mM in the
lower genital tract), where their concentrations vary depending on the
presence or not of infection/inflammation.10,11
The SCFAs are known to modify several cellular processes including
gene expression, chemotaxis, differentiation, proliferation and apop-
tosis. Signaling pathways such as activation of G protein coupled
receptors (GPCRs), inhibition of histone deacetylases (HDACs) and
stimulation of histone acetyltransferase activity, among other pathways
including the recently described stabilization of the hypoxia-inducible
factor (HIF) are implicated in their effects (Figure 1).12–15 SCFAs
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activate at least four different GPCRs: the free fatty acid receptors
(FFAR)-2 and -3, which are also known as GPR43 and GPR41,
respectively, the niacin/butyrate receptor GPR109a (also known as
HCA2) and the olfatory receptor (Olfr)-78.16,17 These receptors show
distinct patterns of expression and they have been partially associated
with the effects of the SCFAs on leukocytes and intestinal epithelial
cells (IECs), as described at the next sections. More details on the
molecular mechanisms and on the effects of SCFAs in other tissues
can be found in different reviews at the literature.14,18
Our aim with this review is to present a clear and updated
description of the effects of the SCFAs derived from bacteria on host
tissues, as well as the molecular mechanisms involved on them. For
this, we used mainly studies published in the last 5 years and focused
in the interaction between these molecules and immune cells.
SCFAS INTERACTIONS WITH INNATE MECHANISMS
OF DEFENSE
The epithelial barriers and the components of innate immune system
are important mechanisms of defense against infection. They act with
the aim of blocking the entrance of microorganisms and, once they
invade the body, rapidly responding to them. In addition, these
mechanisms are regulated by adaptive immune components and
constitute an essential effector mechanism of this other branch of
the immune system.19
EPITHELIAL CELLS
The epithelial barrier is part of the host defense against
microorganisms.19 Epithelial cells not only constitute a physical barrier
to the entrance of microorganisms, but they are also an active
component of the host defense by sensing pathogenic microorganisms
or their molecules such as toxins, and responding to them, as shown
for IECs.19 These cells are source of mucin and antimicrobial peptides
that are secreted to the intestinal lumen, as well as immune mediators
including cytokines and chemokines, which recruit and regulate the
differentiation and activation of immune cells.19
As previously described, SCFAs are found in high concentrations in
the intestine, where they are in close contact with the IECs. These cells
uptake SCFAs through passive (mainly, the non-ionized form) and
active mechanisms. Transporters such as the monocarboxylate
transporter-1 (Slc16a1) and the sodium-dependent monocarboxylate
transporter-1 (Slc5a8) are part of these latter mechanisms responsible
for the passage of these bacterial metabolites from the intestinal lumen
to the cytosol of IECs, where they are partially used as a source of
ATP.18 In this context, IECs metabolize most of the absorbed butyrate,
while propionate is largely taken up by the liver and acetate reaches the
systemic circulation at higher concentrations.18 The relevance of
SCFAs as energy supply for the colonic epithelium has been demon-
strated in different studies. Donohoe et al.20 exemplifies this concept.
These authors showed that colonocytes from germ-free mice present
an energy-deprived state and that after their colonization with
butyrate-producing bacteria in vivo or the addition of butyrate
in vitro to isolated germ-free colonocytes, it was possible to revert
these metabolic alterations leading to an increment in the oxidative
phosphorylation and reduction of the autophagy in these cells.20
Taking into account the fact that SCFAs are important energetic
substrates for epithelial cells, the confirmation that they are regulators
of their proliferation was already expected.12 Interestingly, SCFAs,
mainly butyrate, present different effects on the growth of normal and
tumoral colonocytes. Butyrate inhibits the growth of cancerous colonic
cells, but not of normal colonocytes and, depending on the concen-
tration, it actually increases the proliferation of this latter cell type.12,21
The mechanism proposed for this difference in susceptibility to
butyrate involves the so-called Warburg effect. In brief, cancerous
cells present a metabolic shift from oxidative metabolism to glycolysis
Figure 1 Cellular signaling pathways activated by the short-chain fatty acids. These bacterial metabolites activate membrane receptors called GPCRs (as
FFAR2, FFAR3, GPR109a and Olfr78). They are also able to reach the cytoplasm of the cells through transporters (Slc16a1 and Slc5a8) or passive diffusion
across the plasma membrane (mainly, the non-ionized form) and they modulate the activity of several enzymes and transcription factors including the HIF,
HDACs and histone acetyltransferase (HAT). SCFAs modify several cellular processes including gene expression, chemotaxis, differentiation, proliferation and
apoptosis through these mechanisms.
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with lactic acid formation; this impairs the metabolization of butyrate
leading to its accumulation inside the cells, favoring the inhibition of
HDACs, a mechanism involved in the suppression of cells growth.12
Butyrate, and possibly the other SCFAs, play a role in the
homeostasis of intestinal epithelium through their effects on colono-
cytes proliferation and apoptosis. Butyrate may induce colonocyte
proliferation at the cript of the colon, where its concentration is lower,
while it shows a pro-apoptotic effect close to the lumen, where its
concentration increases, inducing colonocyte exfoliation, contributing
to the normal turnover of cells in this tissue.12 Possibly other effects of
SCFAs in the colon also contribute to their role in the homeostasis of
this tissue including their capacity to induce the production of IL-18,
as described later in this review.
Studies in the literature indicated that SCFAs improve some of the
immune defensive functions of the intestinal epithelium. In this
regard, Raqib et al.22 showed that butyrate increases the expression
of antimicrobial peptides (LL-37 and CAP-18) by epithelial cells of the
large intestine in rabbits and humans. An increment in the cathelicidin
LL-37, but not in other antimicrobial peptides such as human beta
defensins 1 and 3, was observed in humans after treatment with
sodium butyrate enema.23
Another study performed with IECs, in this case from pigs, found
that butyrate increases the expression of β-defensins and cathelicidins,
an effect also observed for acetate and propionate, and extended to
porcine macrophages.24 Although the mechanism behind these effects
of the SCFAs is not completely known, the inhibition of HDAC
activity and consequently the modification in the transcription of
genes responsible for the synthesis of the antimicrobial peptides is
implicated.25 Interestingly, some of these studies have found beneficial
effects of administration of SCFAs in humans, by reducing the
inflammation and increasing the production of LL-37 in patients with
shigellosis, and animals (reduction in Salmonella enteritidis load in
chickens)23,25 suggesting their use for the prevention of enteric
infections.
Kim et al.26 have shown that SCFAs increase the production of
cytokines and chemokines including TNF-α, IL-6, CXCL1 and
CXCL10 by colonic epithelial cells in vitro. This effect was not
observed in cells pre-treated with pertussis toxin (an inhibitor of
G0/i) or in FFAR2- or FFAR3-deficient cells, indicating the involve-
ment of these GPCRs. In vivo, the inflammatory response presented by
FFAR2- and FFAR3-knockout mice after ethanol-induced breach,
trinitrobenzene sulfonic acid treatment or Citrobacter rodentium
infection was abnormally low. This impairment of the immune
response was associated with the absence of SCFAs signals through
FFAR2 or FFAR3 in epithelial cells and a consequent reduction in the
production of inflammatory mediators, which are necessary for an
adequate recruitment of leukocytes and activation of T lymphocytes in
the colon in response to inflammatory stimuli.26
Other studies reported that SCFAs modify the production of
cytokines by IECs. The activation of FFAR2 and GPR109a by SCFAs
in IECs increased the production of IL-18, a key cytokine for the
repair and maintenance of the epithelial integrity.27,28 Macia et al.27
demonstrated that after the binding of SCFAs to these GPCRs, there is
a membrane hyperpolarization and K+ efflux, leading to activation of
NLRP3, which promotes the conversion of pro-IL-18 to IL-18. In
agreement with a previous study,7 the authors of this study found a
protective effect of SCFAs in a colitis model, an effect that was
associated with the activation of NLRP3 and regulation of
inflammation.27
SCFAs can also inhibit the production of some cytokines and
chemokines by epithelial cells. Iraporda et al.29 found that SCFAs
(mainly, butyrate and propionate) reduce the expression of CXCL8
and CCL20 by Caco-2 cells in vitro in response to flagellin stimulation,
an effect that was not related to GPCRs activation. The inhibitory
effect of the SCFAs on CXCL8, an important neutrophil chemoat-
tractant, was also observed in other IECs cell lines and was associated
with the inhibition of HDAC activity.30
SCFAs also act on the epithelial barrier function itself. In this
context, these bacterial metabolites not only increase the production of
IL-18, a cytokine that contributes to the intestinal epithelium home-
ostasis, but also act by other mechanisms including stabilization of the
HIF.15 SCFAs increase oxygen consumption by IECs that leads to a
reduction in oxygen tension, resulting in a stabilization of HIF.15 In
this study, the reduction of number and diversity of intestinal
microbiota components by antimicrobial agents reduced the expres-
sion of HIF-1, which was restored after supplementation with
tributyrin (a pro-drug of butyrate) administration. It is worth
mentioning that HIF is a transcription factor directly involved in the
maintenance of tissue integrity since, among other effects, it regulates
the production of antimicrobial peptides and intestinal epithelial tight
junctions.31,32
Taking together, these studies indicate that SCFAs are essential for
the maintenance of intestinal epithelium physiology both by regulating
the cellular turnover and barrier functions, and for modulating the
response after inflammatory/infectious stimulation. In this latter
condition, however, it is not clear why in some cases these bacterial
metabolites present a pro-inflammatory and prompt the immune
responses,26 whereas in others they have the opposite effect.28 The fact
that different molecular mechanisms are activated by them on a
variety of cell types might partially account for these differences.
NEUTROPHILS
Another important component of the innate immune defenses is the
neutrophil. These cells are normally the first to arrive at the site of
inflammation, where they mount a response to infectious agents and
produce cytokines that initially orchestrate the subsequent recruitment
and activation of other cells including macrophages and even more
neutrophils.
SCFAs interact with neutrophils and modulate their recruitment,
effector function and survival at different tissues (reviewed in
Rodrigues et al.33). These bacterial metabolites alter neutrophils
recruitment by their ability to regulate the production of inflammatory
mediators including cytokines that activate endothelial cells such as
TNF-α and IL-17 and neutrophil-chemoattractants such as CXCL1
and CXCL8 by different cells.26,28–30,34,35 In addition, SCFAs activation
of FFAR2 in neutrophils has been shown to induce their
chemotaxis.7,36,37
Studies using human and rodent neutrophils (in this latter case,
elicited cells) have found that SCFAs modify their production of
inflammatory cytokines. Tedelind et al.38 and our group35 described
an inhibitory effect on the TNF-α production by these cells in the
presence of toll-like receptor (TLRs) agonists and SCFAs.
A reduction in the activation of the transcription factor NF-κB,
which is associated with inhibition of HDAC activity, may account
for this effect.35 However, another recent study described an
increase in the production of CXCL8 by human neutrophils when
incubated with a TLR2 agonist and SCFAs, indicating that the effect
of these bacterial metabolites may depend on the stimuli and state
of activation of the cells.39 Other neutrophil functions including
their capacity to phagocytose particles and microorganisms, to
produce and release toxic molecules such as reactive oxygen species
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and nitric oxygen (NO) and their survival may also be modified by
these bacterial metabolites (revised in Rodrigues et al.33).
MONOCYTES AND MACROPHAGES
It is obvious that not only the epithelial cells or neutrophils are
modulated by the SCFAs. Many studies have been published in the last
few years using different experimental approaches to show that
monocytes and macrophages are also an important target of these
bacterial metabolites. According to Cox et al.,40 the presence of SCFAs
leads to anti-inflammatory effects by regulating the production of
cytokines and prostaglandin E2 (PGE2) by human monocytes. In this
study, the authors cultivated human monocytes in vitro with or
without the SCFAs, pointing out that the presence of these fatty acids
enhanced the production of PGE2, showing a synergistic result when
incubated together with LPS. This result is specifically related to PGE2,
since other lipid mediators as PGI2, LTB4, and TXB2 were tested, but
no effect was observed. Regarding the cytokine profile, there was a
reduction of IL-10 caused by the SCFAs when the cells were stimulated
with LPS, as well as a dose-dependent inhibition of CCL2 production
(with and without LPS). Similar results were obtained in peripheral
blood mononuclear cells with an additional result of inhibition in the
production of LPS-induced TNF-α and IFN-γ.40 Contrary to these
findings, another study described a pro-inflammatory (increase of
IL-1β, IL-6 and CXCL8/IL-8) effect of SCFAs either alone or, in some
cases, combined with TLR agonists, in human peripheral blood
mononuclear cells.39
As demonstrated above, the scientific literature on the SCFAs shows
a lot of divergences. These compounds can act as pro- or anti-
inflammatory molecules depending on the cell type that is studied and
on the conditions, environment and type of stimulation. Bailón et al.41
hypothesized that the effects of the SCFAs, especially butyrate, might
depend on the states of differentiation and proliferation of the
immune cells. To test that, the authors incubated murine bone
marrow-derived macrophages with butyrate, showing a dose-
dependent inhibition of their proliferation. This effect was also seen
in T lymphocytes, although only in this latter cell type a suppression
of activation and induction of apoptosis were observed with the
treatment. The authors repeated the experiment, but using RAW264.7
murine macrophage-like cells, an immortalized cell line that does not
require stopping proliferation before activation. By incubating these
cells with butyrate, the authors found results similar to those observed
in T cells (and, consequently, divergent from the bone marrow-
derived macrophage results), indicating that butyrate leads to an
inhibition of the cells that present high proliferative rates during
activation (T cells), while apparently it is unable to inhibit the cells
that are not proliferating during their activation (tissue macro-
phages).41
The murine macrophage cell line RAW264.7 was also studied by
Liu et al. 42 In this study, cells were incubated with LPS combined with
different concentrations of the SCFAs and, even though there was no
effect in the cellular viability by the MTT test, a significant reduction
in the NO production was observed. The presence of SCFAs also
decreased the LPS-induced production of TNF-α, IL-1β, IL-6,
although, in the meantime, reinforced the LPS-induced production
of IL-10. Interestingly, they also demonstrated that acetate is able to
prevent the LPS-induced p65 protein translocation to the nucleus,
indicating that the suppression of NF-κB intracellular signaling
pathway might be important for the effect of SCFAs. Our group also
reported an inhibitory effect of butyrate on TNF-α production by
RAW264.7 cells stimulated with palmitic acid or LPS.43 Similar results
were obtained in the presence of a potent pan-inhibitor of HDACs
indicating the involvement of this molecular pathway.43
Another study, performed with RAW264.7 cells and rat
thioglycolate-elicited macrophages, showed that butyrate inhibits the
LPS-induced migration of these cells.44 Based on their findings and
previous works, the authors proposed a model to explain this effect.
LPS binds to the TLR4 on these cells, leading to the activation of
NF-κB, which targets iNOS to upregulate Src (a nonreceptor tyrosine
kinase) and ultimately activate FAK (focal adhesion kinase), a kinase
that interacts with the extracellular matrix and the integrin signaling,
and is important for the macrophage migration. In this context,
butyrate acts impairing the NF-κB activation, consequently abolishing
the increase of Src/FAK and so, reducing the motility of these cells.44
More recently, Chang et al.45 demonstrated the anti-inflammatory
effect of butyrate in bone marrow-derived macrophages (a reduction
of NO, IL-6 and IL-12p40, but no alteration in the TNF-α or MCP-1/
CCL2 was observed in cells stimulated with LPS in the presence of
butyrate, but not with propionate or acetate). Similar results were
obtained with macrophages isolated from the colonic lamina propria
both when the cells were incubated in vitro with a combination of
butyrate and LPS, and when this SCFA was given orally to the animals.
The authors showed that butyrate acts through inhibition of the
HDACs. Chromatin immunoprecipitation analyses revealed an
increase of the histone 3 lysine 9 acetylation at the promoter regions
of the genes Nos2, Il2 and Il12b, but not Tnfa. In this study, even
though butyrate acted as an anti-inflammatory molecule, its presence
(given to the mice in the drinking water) did not result in an
improvement of resolution in colitis model. Conflicting results
regarding the effect of SCFAs in colitis were reported by different
groups indicating that differences in the protocol of treatment, model
of colitis or other factors including type of diet may be affecting the
disease outcome.7,28,46
Regarding the production of host defense peptides, Zeng et al.,24 as
cited above, showed that butyrate induces the production of some of
these peptides in a dose-dependent manner in porcine 3D4/31 lung
alveolar macrophages, as well as in primary monocytes, and IPEC-J2
epithelial cells. Besides that, similar results have been described in
humans, rabbits and cattle, but apparently butyrate is not a host
defense peptides inducer in mice.22,47,48 Sunkara et al.,49 using chicken
HD11 macrophage cells and chicken primary monocytes, showed that
the presence of butyrate enhances the expression of many host defense
peptides genes such as Avian β-defensin 9 (AvBD9), cathelicidin B1,
AvBD3, AvBD4, AvBD8, AvBD10 and AvBD14, helping to suppress
bacterial growth. Moreover, by given the chickens butyrate in the
drinking water, there was a reduced colonization of Salmonella
enteriditis in the cecum. However, different than what was described
for mammalian cells, the presence of butyrate did not alter the
production of cytokines as IL-1β, IL-8 and IL-12p40 by avian cells.
Another important aspect is that no changes in the phagocytic capacity
or the oxidative burst of HD11 cells were observed after the treatment
with different concentrations of butyrate.49 A more recent paper of
this group indicated that acetate and propionate also present these
effects.25 Together, these articles demonstrated that SCFAs modulate
macrophage responses.
DENDRITIC CELLS (DCS)
Millard et al.50 investigated whether the SCFAs, specifically butyrate,
could affect macrophages and DCs differentiation and functions.
Using a non-cytotoxic concentration of butyrate, these authors showed
that its addition into a culture of human peripheral blood monocytes
with the proper growth factors to macrophages or DCs differentiation
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(GM-CSF only or GM-CSF and IL-14, respectively) caused important
modifications in their phenotypic differentiation, leading to changes in
the capacity of these cells to capture antigens (confirmed by tests of
phagocytic capacity). Moreover, they also showed that not only
butyrate inhibited the maturation of the DCs when these cells were
incubated with different inducers as TNF-α+PGE2, LPS or even
TNF-α+IL-1β, but it also altered the production of some cytokines
as IL-10 and IL-12 by this cell type. As predicted, DCs pre-treated with
butyrate showed a lower capacity to stimulate T cells.50
A delay in human DCs maturation, characterized by an inhibition
in dendrite formation and expression of surface markers as CD80,
CD83, CD1a and MHC class II molecules (which are highly expressed
on mature DCs), was observed in the presence of butyrate.42 DCs
treated with butyrate had a lower capacity of stimulating T cells and
showed a reduction in the production of pro-inflammatory cytokines
as IL-12p40 and IFN-γ. In contrast, DCs treated with butyrate released
much higher amounts of the anti-inflammatory cytokine IL-10.42
Other studies have also described a reduction in the expression of
surface markers associated with the maturation of DCs such as CD40,
CD80 and CD86 in cells incubated with butyrate or the other
SCFAs.51,52 In addition, a study reported that butyrate increases the
production of IL-23 by DCs, an effect with important implications for
the polarization of T cells.51
Singh et al.53 investigated the mechanisms by which the SCFAs
regulate DCs development and function. In this study, butyrate
suppressed DCs development, but not their functional maturation
after LPS stimulation. This effect on DCs development was also
observed in cells incubated with propionate, but not acetate.53
According to the authors, the ability of these compounds to inhibit
the HDACs, thus suppressing the expression of important transcrip-
tion factors for DC development such as PU.1 and RelB, is involved in
their effects on this cell type. Interestingly, this study also revealed that
these modulations are in fact dependent on the butyrate-transporter
Slc5a8,53 whose role in the effects of SCFAs in DCs and other immune
cells was explored in more details in another study.54
In summary, it is now well-established that SCFAs modulate
different aspects of innate immune response, even though there are
still some controversies in the literature. The actions of SCFAs on
innate immunity also affect the activation (SCFAs have been shown
to impair DCs development affecting their ability to stimulate
T lymphocytes) and the effector response of the components
of the adaptive immunity. In addition, direct effects of SCFAs on
T lymphocytes have already been reported, as described in the next
section of this review.
IMPACT OF THE SCFAS ON THE ADAPTIVE IMMUNE SYSTEM
The SCFAs modulate T-lymphocytes activation and effector responses.
Several studies have shown that SCFAs, in general, induce a
T-lymphocyte tolerogenic profile, which depends on their actions in
the activation/differentiation of DCs and macrophages as well as direct
effects on lymphocytes.
Gurav et al.54 have found that DCs treated in vitro with butyrate
and, to a lesser extend with propionate, present an increment in the
expression of indoleamine 2,3-dioxygenase 1 and aldehyde dehydro-
genase 1A2. These enzymes attenuate the immune activation through
triptophan depletion (IDO) and generation of retinoic acid (aldehyde
dehydrogenase 1A2), a molecule with immunesuppressive properties.
These effects, together with other SCFAs actions on DCs, potentiate
the ability of these cells to convert naïve T cells into FoxP3+ regulatory
T cells (Tregs) and to suppress their conversion into pro-inflammatory
T cells (IFN-γ+ T cells).54 In accordance with Singh et al.,53 the
authors indicated the involvement of the Slc5a8 transporter and,
possibly, the inhibition of HDACs activity, in the effects of SCFAs
on DCs. 54
Singh et al.28 demonstrated that butyrate activation of GPR109a in
macrophages and DCs is essential for maintaining the balance between
pro- and anti-inflammatory CD4+ T cells. In this study, the authors
found that GPR109a-deficient mice (GPR109a KO) have a reduction
in CD4+ T-cells-producing IL-10 and an increase of IL-17-producing
T cells. This phenotype was associated with the absence of GPR109a
signaling activated, possibly, by butyrate derived from the microbiota,
in the GPR109a KO animals. Macrophages and DCs incubated
with butyrate or niacin (other agonist of GPR109a) showed an
increase in expression of l10 and Aldh1a1, which contribute for the
differentiation of naive T cells to regulatory T lymphocytes. In
addition, the authors found, as previously discussed, that butyrate
increased the expression of IL-18 in colonic epithelium. Together,
these effects of GPR109a agonists may explain why GPR109a KO mice
are more susceptible to colitis, intestinal inflammation and carcino-
genesis.28
SCFAs induce generation of Tregs not only through their effects on
DCs, but also by theirs direct interaction with T lymphocytes. In this
context, Arpaia et al.55 demonstrated that butyrate facilitates extra-
thymic peripheral polarization to Treg Foxp3+ both in vivo and
in vitro. In vivo, there was a significant increase in the amount of
peripheral regulatory T cells in antibiotic-treated mice that received
butyrate in the drinking water, a pattern that was not seen in the
thymus or in the colon. Using mice deficient in a Foxp3 enhancer, the
conserved noncoding sequence 1 (these animals have an intact thymic
differentiation, but present a deficient peripheral generation of Treg
cells), the authors showed that this increase in Tregs by SCFAs
(propionate and butyrate) was due to the extra-thymic generation of
these cells. The proposed mechanism for these effects of SCFAs was
the inhibition of HDACs.55 Another study has found that the
generation of peripheral regulatory T cells in the colon by a class of
commensal bacteria that predominates in the intestinal tract, the
Clostridia class, is associated with their production of butyrate
in vivo.56 In agreement with Arpaia et al,55 the mechanism proposed
in this study for the Treg-cell-polarizing effect of butyrate was the
inhibition of HDACs. The inhibition of this class of enzymes leads to
an enhanced histone H3 acetylation in the locus of Foxp3 and increases
the expression of this transcription factor.56 The activation of FFAR2
also seems to play a role in the effect of SCFAs in the Treg
generation.46
SCFAs can also affect Th1, Th2 and Th17 polarization and
activation. Trompette et al.4 have shown that SCFAs produced in
the intestine impair Th2 polarization. The authors found that mice fed
with a fiber-enriched diet (increased circulating levels of SCFAs) are
more resistant against allergic processes in the lungs. The opposite
phenotype was observed in animals fed with a low-fiber diet. This
effect was associated with the ability of SCFAs (mainly, propionate) to
modify hematopoiesis and increase the generation of precursors of
macrophages and DCs with low MHC-II and CD40 expression, and
increased phagocytic capacity. In this sense, animals, previously treated
with propionate, showed increased recruitment of these cells, which
are less effective in reactivating Th2 cells, to lung-draining lymph
nodes. Likewise, there were fewer eosinophils, IgE and cytokines such
as IL-4 and IL-13 in the lung of these animals. Interestingly, the
authors showed that these effects are dependent of FFAR3, but
independent of FFAR2. 4 In this context, a recent study showed that
high-fiber diet or acetate administration protected mice against the
development of allergic airways disease.57 Interestingly, high-fiber/
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acetate feeding of pregnant mice also led to a reduction in allergic
airways disease development by their adult offspring. This study also
provides evidence for a role of diet and acetate production in the
development of airway disease in humans.57
Nevertheless, Park et al.58 have demonstrated that acetate, propio-
nate and butyrate enhance the naïve T-cell polarization not only to
Tregs, but also promote the generation of Th17 and Th1 effector cells
in vitro. Interestingly, however, the Th1 and Th17 cells induced in vitro
in the presence of SCFAs presented a less inflammatory profile in vivo
in a colitis model. The authors indicated that this is associated with the
ability of SCFAs to induce IL-10-producing T cells together with Th1
and Th17 effector T cells. The effect of the SCFAs in the T cells was
again associated with the inhibition of HDACs, but in this case mTOR
activation was also suggested to participate in the mechanism.58 Other
study, in which, splenocytes were co-cultured with LPS-stimulated
DCs, reported that butyrate treatment in vitro caused a significant
induction of IL-17 and IL-10. However, in this study, the authors
found that oral administration of butyrate increased colitis severity.51
SCFAs are also able to modulate T-cells proliferation and apoptosis. A
low concentration of butyrate was shown to inhibit the proliferation of
both CD4+ and CD8+ T cells in vitro. This study also reported
an induction of apoptosis in T cells through a Fas-dependent
mechanism.59
Taking together, these studies suggest that SCFAs affect the
activation and effector function of T cells. However, despite the fact
that most of the studies support the idea that SCFAs induce a
tolerogenic and anti-inflammatory profile of T cells, evidences also
indicate that under some conditions they may induce Th1 and Th17
responses, and, depending on the disease/model and other factors
including time, route and concentrations of treatment used, they can
both ameliorate or worsen the disease severity.51,52,58,60
CONCLUDING REMARKS AND PERSPECTIVES IN THE FIELD
The interaction between microbiota and immune system is bidirec-
tional and involves different components/mechanisms, which are
beginning to be identified and understood in physiological and
pathological states. SCFAs, as described in this review, are an
important link between microbiota and immune system. This inter-
action involves different molecular mechanisms and cellular targets, as
summarized in the Figure 2, and it is essential for the maintanence of
intestinal homeostasis and also plays a role in the development of
diseases. Despite the advances in the field, several aspects of this
interaction remain unclear or need to be studied in more details as
indicated by the conflicting results described in the literature.
Our expectation is that this flourishing area of research will impact
on our knowledgement on the mechanisms by which diet, microbiota
and also other factors influence the functioning of immune system
and, consequently, the development of inflammatory and infectious
diseases. In this context, it is important to mention that this knowl-
edge will open opportunities for developing novel and more effective
therapies for the treatment of chronic inflammatory diseases.
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Figure 2 The SCFAs are bacterial fermentation products found in high concentrations in the intestine. These metabolites act as a link between the
microbiota and the immune system. IECs uptake SCFAs through passive (mainly, the non-ionized form) and active mechanisms. Once inside the cells, they
are partially used as a source of energy (1). In addition, these SCFAs increase the expression of antimicrobial peptides secreted to the external surface by
epithelial cells (2) and modulate their production of immune mediators including IL-18, a key cytokine for the repair and maintenance of epithelial integrity,
and others cytokines and chemokines (3). SCFAs can also regulate the differentiation, recruitment and activation of immune cells: including neutrophil (4),
DCs (5), macrophages (6) and T lymphocytes (7). In this context, SCFAs interact with neutrophils and modulate their recruitment, effector function and
survival at the tissues (4). In general, these bacterial metabolites present anti-inflammatory effects including reduction of some pro-inflammatory cytokines
such as TNF-α and IL-12 production by macrophages and DCs, and change their capacity to capture antigens and stimulate T cells. In addition, the SCFAs
also modulate the proliferation and differentiation of T lymphocytes through direct effects on these cells (for example, inducing the generation of Tregs) (7).
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